Aurobindo Pharma's API unit clears USFDA inspection with two observations
The story in brief
Aurobindo Pharma's API unit, located in Andhra Pradesh, cleared a USFDA inspection with two observations following the review conducted between 22 June and 26 June 2026. The company reiterated its commitment to maintaining the highest quality manufacturing standards, stating it will respond to the observations within the stipulated timeline, while its stock advanced 1.65% to end at Rs 1,554.95 on the BSE.